Metformin

This HPLC method presents the analysis of diabetic drugs Empagliflozin and Metformin utilizing an Amaze SC Mixed-Mode Column. The separation is conducted in both reversed-phase and cation-exchange modes, ensuring baseline separation of both compounds. Order of elution for both compounds can be changed by exploring differences in hydrophobic and ionic properties of Empagliflozin and Metformin. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. It is a hydrophilic compound with moderate water solubility. Empagliflozin contains an aromatic ring structure with multiple functional groups, including hydroxyl and glucose moiety, which contribute to its hydrophilic/hydrophobic nature. Metformin is a biguanide antidiabetic medication commonly prescribed to control blood sugar levels in individuals with type 2 diabetes. It is highly water-soluble and possesses basic properties due to the presence of amino groups. Metformin contains a hydrophilic amino group and exhibits a moderate degree of polarity and basicity. The Amaze SC Mixed-Mode Column is selected for its dual functionality in reversed-phase and cation-exchange modes. In reversed-phase mode, the hydrophobic interactions between the analytes and the stationary phase enable separation based on differences in hydrophobicity. In cation-exchange mode, the column facilitates selective retention and separation of positively charged species, such as metformin, based on ionic interactions. By employing this HPLC method, precise quantification and characterization of Empagliflozin and Metformin can be achieved, providing valuable insights into their pharmaceutical formulations and therapeutic efficacy in managing diabetes.

Amaze SC PURCHASE LEARN ABOUT Amaze SC

Conditions of Experiment

Column:	Amaze SC
Separation Modes:	reversed-phase, cation-exchange
Column Dimenstions:	4.6x150 mm, 3 um, 100 A
Mobile Phase:	ACN/water/sulfuric acid
Detection:	235 nm
Sample:	0.3-0.3 mg/ml
Injection:	3 uL
Flow rate:	1 ml/min

Analytes

Class of compounds:	Drug
Nature of compounds:	Basic, Hydrophilic, Hydrophobic, Neutral, Polar
Compounds:	Empagliflozin, Metformin

Metformin is an antidiabetic drug that helps with reducing blood glucose levels and improves insulin sensitivity. It is used to control Type 2 diabetes. Metformin is a guanidine type of compound which is polar and basic in nature. The addition of ion-pairing reagents is required to achieve retention time in RP chromatography. Metformin was analyzed without the use of an ion-pairing reagent on the Coresep 100 mixed-mode column. The retention time of metformin is controlled by an ion-exchange mechanism and can be adjusted by varying the buffer concentration and buffer pH. The amount of ACN will have a limited effect on RP retention but affects ionization state of stationary phase and metformin. Various mobile phases can be used with the Coresep 100 column to accommodate numerous detection techniques. UV transparent buffers can be replaced with volatile buffers for MS, ELSD or CAD detection. This method and the mixed-mode HPLC column can be used for the analysis of metformin and other hydrophilic/basic compounds without ion-pairing reagents. Core-shell mixed-mode columns provide great combination of unique selectivity, speed and efficiency.

Coresep 100 PURCHASE LEARN ABOUT Coresep 100

Conditions of Experiment

Column:	Coresep 100
Separation Modes:	reversed-phase and cation-exchange
Column Dimenstions:	3.2 x 100 mm, 2.7 um, 90A
Mobile Phase:	MeCN 20% with 0.12% phosphoric acid
Detection:	UV 275 nm
Sample:	0.1-0.3 mg/ml
Injection:	1 uL
Flow rate:	0.6 mL/min

Analytes

Class of compounds:	Drug
Nature of compounds:	Basic, Hydrophilic, Polar
Compounds:	Metformin